| Offering Information |
| Expected Date | - |
| Proposed Exchange/Ticker |
Nasdaq: ABGX |
| Security Type |
Common Stock |
| Lead Underwriter |
BancAmerica Robertson Stephens |
| Days In Registration |
90 |
| Date Filed |
3-Apr-1998 |
| Form Filed | S-1 |
Fundamentals
(Year Ending December 2007) |
| Industry |
Pers/Bus/Rep Svc |
| Business Description |
Provide research development services for antibody therapeutic products for the prevention and treatment of a variety of disease conditions, including transplant-related diseases, inflammatory and autoimmune disorders, and cancer |
| Revenue |
- |
| Net Income |
- |
| Shares Outstanding (post-offering) |
44.22M |
| President/CEO |
R. Scott Greer |
| Number of Employees |
243 |
|
| Original Filing Information |
| US |
| Shares Filed |
3.0M |
| Secondary Shares Filed | - |
| · As a Percent |
- |
| Primary Shares Filed |
3.0M |
| · As a Percent |
100.0 |
| Overallotment Shares Filed |
375.0K |
| File Amount |
$33.0M |
| File Price Range |
$12.00 - $10.00 |
| File Mid Price |
$11.00 |
Current Filing Information
(Amended 2-Jul-1998) |
|
US |
|
Shares Filed |
2.5M |
| Secondary Shares Filed |
- |
| · As a Percent |
- |
| Primary Shares Filed |
2.5M |
| · As a Percent |
100.0 |
| Overallotment Shares Filed |
- |
| File Amount |
$20.0M |
| · % Change from Original |
-39.39 |
| File Price Range |
$8.00 - $8.00 |
| File Mid Price |
$8.00 |
|
